ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2434

Risk of Lymphoma and Thyroid Cancer in Primary Sjögren’s Syndrome Measured Using the Korean Health Insurance Claims Database

Joong Kyong Ahn 1, Jiwon Hwang2 and Gi Hyeon Seo 3, 1Division of Rheumatology, Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea, 2Division of Rheumatology, Department of Internal Medicine, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon-si, Republic of Korea, 3Health Insurance Review and Assessment Service, Wonju, Republic of Korea

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: lymphoma, Sjogren's syndrome, thyroid cancer and incidence

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 12, 2019

Title: Sjögrenʼs Syndrome – Basic & Clinical Science Poster I

Session Type: Poster Session (Tuesday)

Session Time: 9:00AM-11:00AM

Background/Purpose: The development of lymphomas is one of the most serious complications of SjS but the incidence, prevalence and estimated risk of lymphoma in primary SjS vary significantly worldwide. Meanwhile, studies from Taiwan and Spain, the estimated risk of thyroid cancer appears slightly increased in primary SjS compared with previous results. Although primary SjS is a very rare disease and many cases are required to determine the exact risk of malignancy in this condition, most epidemiological studies of primary SjS have been limited to a small number of cases such as case-control studies, leading to low-quality evidence. A large sample size with a significant number of cases is therefore required to analyse the risk of lymphoma and thyroid cancer in primary SjS. The aim of this study was to evaluate the incidence and risk of lymphoma and thyroid cancer in patients with primary Sjögren’s syndrome (SjS) employing a large-scale assessment based on the Korean National Health Insurance Service (NHIS) claims database.

Methods: Primary SjS was identified using the Korean NHIS medical claims database between 2007 and 2017. The case definition required more than one visit based on the Sjögren’s syndrome diagnostic code and the registration system for rare and incurable diseases. A 3-year washout period was applied in our study to exclude patients who were diagnosed before their information was entered into the national rare and incurable disease database. The presence of a connective tissue disease before the SjS diagnosis and within one year after the SjS diagnosis was ruled out in order to recruit primary SjS only. We included all admissions with a primary diagnosis of lymphoma and thyroid cancer.

Results: The primary SjS incidence was 1.88 cases/100,000 inhabitants. Female patients had a higher incidence than male patients, with a female-to-male ratio of 7.65:1. For primary SjS, the standardised incidence ratios for lymphoma and thyroid cancer were 4.66 (95% confidence interval [CI] 2.69–7.55) and 1.23 (95% CI 0.88–1.68), respectively. The lymphoma risk was 4.66-fold higher among the patients with primary SjS than in the general population. Compared with the general population, female patients with primary SjS had a 5.32-fold higher risk of developing lymphoma, while the male patients did not. Patients with primary SjS did not have a higher risk of developing thyroid cancer.

Conclusion: Primary SjS is associated with a higher risk of developing lymphoma. The lymphoma risk appears to have decreased compared with that in previous studies. Our study suggests that the risk of lymphoma or thyroid cancer with SjS is not higher than that reported in previous studies.


2019 ACR table_SjS

Incidence and SIR and 95% CI for lymphoma and thyroid cancer in patients with primary Sjögren’s syndrome


Disclosure: J. Ahn, None; J. Hwang, None; G. Seo, None.

To cite this abstract in AMA style:

Ahn J, Hwang J, Seo G. Risk of Lymphoma and Thyroid Cancer in Primary Sjögren’s Syndrome Measured Using the Korean Health Insurance Claims Database [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/risk-of-lymphoma-and-thyroid-cancer-in-primary-sjogrens-syndrome-measured-using-the-korean-health-insurance-claims-database/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/risk-of-lymphoma-and-thyroid-cancer-in-primary-sjogrens-syndrome-measured-using-the-korean-health-insurance-claims-database/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology